tradingkey.logo
tradingkey.logo
Buscar

Sonoma Pharmaceuticals Inc

SNOA
Añadir a la lista de seguimiento
1.210USD
0.0000.00%
Cierre 07/02, 13:00ETCotizaciones retrasadas 15 min
2.09MCap. mercado
PérdidaP/E TTM

Más Datos de Sonoma Pharmaceuticals Inc Compañía

Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.

Información de Sonoma Pharmaceuticals Inc

Símbolo de cotizaciónSNOA
Nombre de la empresaSonoma Pharmaceuticals Inc
Fecha de salida a bolsaJan 26, 2007
Director ejecutivoTrombly (Amy)
Número de empleados168
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 26
Dirección5445 Conestoga Court, Suite 150
CiudadBOULDER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal80301
Teléfono18007599305
Sitio Webhttps://sonomapharma.com/
Símbolo de cotizaciónSNOA
Fecha de salida a bolsaJan 26, 2007
Director ejecutivoTrombly (Amy)

Ejecutivos de Sonoma Pharmaceuticals Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jay E. Birnbaum, Ph.D.
Dr. Jay E. Birnbaum, Ph.D.
Independent Director
Independent Director
286.00
-0.35%
Mr. Jerry G. Mclaughlin
Mr. Jerry G. Mclaughlin
Lead Independent Director
Lead Independent Director
--
--
Mr. Philippe Weigerstorfer
Mr. Philippe Weigerstorfer
Independent Director
Independent Director
--
--
Ms. Amy Trombly
Ms. Amy Trombly
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jerry Dvonch
Mr. Jerry Dvonch
Chief Financial Officer
Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jay E. Birnbaum, Ph.D.
Dr. Jay E. Birnbaum, Ph.D.
Independent Director
Independent Director
286.00
-0.35%
Mr. Jerry G. Mclaughlin
Mr. Jerry G. Mclaughlin
Lead Independent Director
Lead Independent Director
--
--
Mr. Philippe Weigerstorfer
Mr. Philippe Weigerstorfer
Independent Director
Independent Director
--
--
Ms. Amy Trombly
Ms. Amy Trombly
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jerry Dvonch
Mr. Jerry Dvonch
Chief Financial Officer
Chief Financial Officer
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Sonoma Pharmaceuticals Inc?

Los cinco principales accionistas de Sonoma Pharmaceuticals Inc son: Dr. Jay E. Birnbaum, Ph.D.

¿Cuántas instituciones poseen acciones de Sonoma Pharmaceuticals Inc (SNOA)?

A fecha de 2026Q1, 40 instituciones poseen acciones de Sonoma Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 127.80K, lo que representa el 3.68% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -34692.00.

¿Cuál es la mayor fuente de ganancias de Sonoma Pharmaceuticals Inc?

El 2026Q1, el segmento empresarial Human Care generó la ganancia más alta para Sonoma Pharmaceuticals Inc, ascendiendo a 3.86M y representando el 88.83% de la ganancia total.